Perkembangan Terkini Terapi Antikoagulan Pada Pasien Covid-19 Bergejala Berat
Article Sidebar
Main Article Content
Abstract
Penyakit covid-19 yang disebabkan oleh virus sarcov-2 awalnya hanya dinyatakan sebagai penyakit pernafasan, namun kemudian diketahui dampak dari penyakit ini dapat menyebabkan kerusakan multiorgan karena adanya fenomeda badai sitokin yang menyebabkan inflamasi dimana-mana termasuk pada pembuluh darah yang menuju berbagai organ penting. Tulisan ini bertujuan untuk mengungkap seberapa signifikan fenomeda koagulasi darah hasil kerja virus covid-19 ini hingga menyebabkan manifestasi tromboembolisme baik dalam terminologi tromboemboli vena, deep vein thrombosis, tromboemboli paru dan lain-lain, juga kemungkinan mekanisme yang terjadi dan yang terpenting dalam tulisan ini adalah seberapa efektifkah penggunaan obat antikoagulan pada pasien covid-19 bergejala berat.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.
References
Long, B, Brady, WJ, Koyfman, A, and Gottlieb, M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504-07. https://doi.org/10.1016/ j.ajem.2020.04.048.
Bansal, M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50. https://doi.org/10.1016/j.dsx.2020.03.013.
He, XW, et al. [Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(6):456-60. https://doi.org/10.3760/cma.j.cn112148-20200228-00137.
Tam, CF, et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020;13(4):e006631. https://doi.org/10.1161/circoutcomes.120.006631.
Lee, IC, Huo, TI, and Huang, YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020;83(6):521-23. https://doi.org/10.1097/jcma.0000000000000319.
Garrido, I, Liberal, R, and Macedo, G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52(2):267-75. https://doi.org/10.1111/apt.15813.
Adapa, S, et al. COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation. J Clin Med Res. 2020;12(6):352-61. https://doi.org/10.14740/jocmr4200.
Gabarre, P, et al. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020;46(7):1339-48. https://doi.org/10.1007/s00134-020-06153-9.
Hayek, SS, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020;371:m3513. https://doi.org/10.1136/bmj.m3513.
Cui, S, Chen, S, Li, X, Liu, S, and Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of thrombosis and haemostasis : JTH. 2020;18(6):1421-24. https://doi.org/10.1111/jth.14830.
Klok, FA, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research. 2020;191:145-47. https://doi.org/10.1016/ j.thromres.2020.04.013.
Klok, FA, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-50. https://doi.org/10.1016/j.thromres.2020.04.041.
Ren, B, et al. Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan. Circulation. 2020;142(2):181-83. https://doi.org/10.1161/circulationaha.120.047407.
Belen-Apak, FB and Sarialioglu, F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020;50(2):278-80. https://doi.org/10.1007/s11239-020-02129-0.
Artifoni, M, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50(1):211-16. https://doi.org/10.1007/s11239-020-02146-z.
Llitjos, J-F, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Journal of thrombosis and haemostasis : JTH. 2020;18(7):1743-46. https://doi.org/10.1111/jth.14869.
Lodigiani, C, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. https://doi.org/10.1016/j.thromres.2020.04.024.
Maatman, TK, et al. Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019. Crit Care Med. 2020;48(9):e783-e90. https://doi.org/10.1097/ccm.0000000000004466.
Middeldorp, S, et al. Incidence of venous thromboembolism in hospitalized patients with COVIDâ€19. Journal of Thrombosis and Haemostasis. 2020;18(8):1995-2002. https://doi.org/10.1111/jth.14888.
Han, H, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116-20. https://doi.org/10.1515/cclm-2020-0188.
Shi, L, Wang, Y, Wang, YD, Duan, GC, and Yang, HY. D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients. Eur Rev Med Pharmacol Sci. 2020;24(16):8576-79. https://doi.org/10.26355/eurrev_202008_22655.
Al-Samkari, H, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500. https://doi.org/ 10.1182/blood.2020006520.
Cheng, A, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. International journal of antimicrobial agents. 2020;56(3):106110-10. https://doi.org/10.1016/j.ijantimicag.2020.106110.
Sakka, M, et al. Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. Journal de medecine vasculaire. 2020;45(5):268-74. https://doi.org/10.1016/ j.jdmv.2020.05.003.
Tang, N, Li, D, Wang, X, and Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis : JTH. 2020;18(4):844-47. https://doi.org/10.1111/jth.14768.
Wu, C, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine. 2020;180(7):934-43. https://doi.org/10.1001/jamainternmed. 2020.0994.
Zhang, L, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of thrombosis and haemostasis : JTH. 2020;18(6):1324-29. https://doi.org/10.1111/jth.14859.
Price, LC, McCabe, C, Garfield, B, and Wort, SJ. Thrombosis and COVID-19 pneumonia: the clot thickens! The European respiratory journal. 2020;56(1):2001608. https://doi.org/10.1183/13993003.01608-2020.
Pizzolo, F, et al. Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. Thrombosis Research. 2020;194:216-19. https://doi.org/10.1016/j.thromres.2020.08.008.
Aid, M, et al. Vascular Disease and Thrombosis in SARS-CoV-2 Infected Rhesus Macaques. Cell. 2020. https://doi.org/ https://doi.org/10.1016/j.cell.2020.10.005.
Rico-Mesa, JS, et al. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Current cardiology reports. 2020;22(7):53-53. https://doi.org/ 10.1007/s11886-020-01328-8.
Kollias, A, et al. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-47. https://doi.org/10.1111/bjh.16727.
Tang, N, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-99. https://doi.org/10.1111/jth.14817.
Paranjpe, I, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(1):122-24. https://doi.org/10.1016/j.jacc.2020.05.001.
DeSancho, MT. Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) (IMPACT). 2020 [cited 2020 october 10]; Available from: https://clinicaltrials.gov/ct2/show/NCT04406389.